{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-061973","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2026-09-15T12:31:45+00:00","discovered_at":"2026-09-15T12:35:00.314804+00:00","generated_at":"2026-09-15T12:35:11.568785+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"BioMarin discontinues VOXZOGO development for Noonan syndrome","bullets":["Decision announced Sept 15, 2026; development halted for Noonan syndrome indication.","Cites study feasibility and current treatment landscape as reasons.","Company states decision not related to safety or efficacy of VOXZOGO."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-061973","json":"https://secwatch.observer/filing/0001628280-26-061973.json","markdown":"https://secwatch.observer/filing/0001628280-26-061973.md","text":"https://secwatch.observer/filing/0001628280-26-061973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026061973/0001628280-26-061973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026061973/bmrn-20260915.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-15T12:35:11.568785+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}